Echo Therapeutics, Inc. (OTC BB: ECTE) has their focus on thelate-stage development of transdermal diagnostic devices as well as specialty pharmaceuticals. The company is currently developing a needle-free, transdermal continuous glucose monitoring system in conjunction with novel transdermal reformulations of existing FDA-approved products. Echo Therapeutics hopes to change the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets. For further information, visit the Company’s web site at www.echotx.com.
- 18 years ago
QualityStocks
Echo Therapeutics, Inc. (OTC BB: ECTE)
Related Post
-
QualityStocksNewsBreaks – Why TruGolf Holdings Inc. (NASDAQ: TRUG) Is ‘One to Watch’
TruGolf (NASDAQ: TRUG) is pursuing a strategic expansion into blockchain-based financial infrastructure through its pending…
-
QualityStocksNewsBreaks – Versus Systems Inc. (NASDAQ: VS) Brings Interactive Experiences to Major Sports and Entertainment Audiences
Versus Systems (NASDAQ: VS) uses gamification and audience engagement technology to help brands, sports teams,…
-
QualityStocksNewsBreaks – BOXABL Inc. (NASDAQ: BXBL) Builds Momentum with Potential 1,500-Home Pipeline
BOXABL (NASDAQ: BXBL) has signed a multiyear purchase agreement with LC Vegas Acquisitions, LLC for…